#remibrutinib
Remibrutinib
Chemical compound
Remibrutinib is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria. In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.
Wed 24th
Provided by Wikipedia
This keyword could refer to multiple things. Here are some suggestions:
0 searches
This keyword has never been searched before
This keyword has never been searched for with any other keyword.